Resources from the same session
228MO - PALOMA-4: Primary results from a phase III trial of palbociclib (PAL) + letrozole (LET) vs placebo (PBO) + LET in Asian postmenopausal women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative (ER+/HER2–) advanced breast cancer (ABC)
Presenter: Binghe Xu
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
229MO - Overall survival (OS) of palbociclib (P) plus endocrine therapy (ET) versus capecitabine (CAP) in hormone-receptor+/HER2- metastatic breast cancer (MBC) that progressed on aromatase inhibitors (AIs): Final results of the PEARL study
Presenter: Miguel Martin Jimenez
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
230MO - First in human, modular study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced solid malignancies
Presenter: Matthew Krebs
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA18 - POSEIDON randomized phase II trial: Tamoxifen (TAM) + taselisib or placebo (PLA) in patients (pts) with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC)
Presenter: Mafalda Oliveira
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
LBA19 - A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (mBC) (DESIREE)
Presenter: Sibylle Loibl
Session: Mini oral session - Breast cancer, metastatic
Resources:
Abstract
Slides
Webcast
Discussion 228MO and 229MO
Presenter: Maria Vittoria Dieci
Session: Mini oral session - Breast cancer, metastatic
Resources:
Slides
Webcast